Slingshot members are tracking this event:

Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Results released at the American Academy of Dermatology (AAD) conference of three Phase 3 studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) of Ixekizumab showed that patients treated with Ixekizumab improved work productivity compared to patients treated with placebo.  In UNCOVER-1 and UNCOVER-2, patients treated with ixekizumab showed significantly greater improvement compared to placebo when evaluated based on absenteeism, presenteeism, work productivity loss and activity impairment.  UNCOVER-3 showed statistically significant improvements compared to placebo in the same areas.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Uncover-1, Uncover-2, Uncover-3, Skin Lesions, Plaque Psoriasis, Work Productivity, Dermatologic Diseases, Ixekizumab